The Apex Times
Above the Noise
Business Wire
BusinessUPS expands air cargo and package terminal in the Philippines to strengthen Asia networkThe Apex TimesBusinessAMD’s data center surge fuels long-term bull case, but valuation and volatility loom largeThe Apex TimesBusinessNetflix shares slip after chief content officer Bela Bajaria’s exit; Peter Rice named to take overThe Apex TimesBusinessNVIDIA flags a new Taiwan export-control risk, with Super Micro the near-term pressure pointThe Apex TimesBusinessNvidia Adds New Variants to Nemotron 3.5 Open AI Model Lineup, While Report Cites Texas Supply Expansion and Customer Debt PressureThe Apex TimesBusinessModerna shares fall after sharp rally as investors reassess valuationThe Apex TimesBusinessMeta launches Muse Spark Open for developers, pairing an open model with its proprietary Muse Wonder systemThe Apex TimesBusinessTesla shares take flight in market chat as iPhone Duo pre-orders sell out and bond yields pause their climbThe Apex TimesBusinessCoreWeave shares fall again as Nvidia’s Jensen Huang’s optimism fails to steady investor sentimentThe Apex TimesBusinessLeftovers: Ghirardelli and PepsiCo lean into TikTok-style flavor and convenience playsThe Apex TimesBusinessModerna shares surge, but some investors are pressing pauseThe Apex TimesBusinessUnitedHealth frames its next growth path around the care it delivers as it lifts 2026 outlookThe Apex TimesBusinessUPS expands air cargo and package terminal in the Philippines to strengthen Asia networkThe Apex TimesBusinessAMD’s data center surge fuels long-term bull case, but valuation and volatility loom largeThe Apex TimesBusinessNetflix shares slip after chief content officer Bela Bajaria’s exit; Peter Rice named to take overThe Apex TimesBusinessNVIDIA flags a new Taiwan export-control risk, with Super Micro the near-term pressure pointThe Apex TimesBusinessNvidia Adds New Variants to Nemotron 3.5 Open AI Model Lineup, While Report Cites Texas Supply Expansion and Customer Debt PressureThe Apex TimesBusinessModerna shares fall after sharp rally as investors reassess valuationThe Apex TimesBusinessMeta launches Muse Spark Open for developers, pairing an open model with its proprietary Muse Wonder systemThe Apex TimesBusinessTesla shares take flight in market chat as iPhone Duo pre-orders sell out and bond yields pause their climbThe Apex TimesBusinessCoreWeave shares fall again as Nvidia’s Jensen Huang’s optimism fails to steady investor sentimentThe Apex TimesBusinessLeftovers: Ghirardelli and PepsiCo lean into TikTok-style flavor and convenience playsThe Apex TimesBusinessModerna shares surge, but some investors are pressing pauseThe Apex TimesBusinessUnitedHealth frames its next growth path around the care it delivers as it lifts 2026 outlookThe Apex TimesBusinessUPS expands air cargo and package terminal in the Philippines to strengthen Asia networkThe Apex TimesBusinessAMD’s data center surge fuels long-term bull case, but valuation and volatility loom largeThe Apex TimesBusinessNetflix shares slip after chief content officer Bela Bajaria’s exit; Peter Rice named to take overThe Apex TimesBusinessNVIDIA flags a new Taiwan export-control risk, with Super Micro the near-term pressure pointThe Apex TimesBusinessNvidia Adds New Variants to Nemotron 3.5 Open AI Model Lineup, While Report Cites Texas Supply Expansion and Customer Debt PressureThe Apex TimesBusinessModerna shares fall after sharp rally as investors reassess valuationThe Apex TimesBusinessMeta launches Muse Spark Open for developers, pairing an open model with its proprietary Muse Wonder systemThe Apex TimesBusinessTesla shares take flight in market chat as iPhone Duo pre-orders sell out and bond yields pause their climbThe Apex TimesBusinessCoreWeave shares fall again as Nvidia’s Jensen Huang’s optimism fails to steady investor sentimentThe Apex TimesBusinessLeftovers: Ghirardelli and PepsiCo lean into TikTok-style flavor and convenience playsThe Apex TimesBusinessModerna shares surge, but some investors are pressing pauseThe Apex TimesBusinessUnitedHealth frames its next growth path around the care it delivers as it lifts 2026 outlookThe Apex TimesBusinessUPS expands air cargo and package terminal in the Philippines to strengthen Asia networkThe Apex TimesBusinessAMD’s data center surge fuels long-term bull case, but valuation and volatility loom largeThe Apex TimesBusinessNetflix shares slip after chief content officer Bela Bajaria’s exit; Peter Rice named to take overThe Apex TimesBusinessNVIDIA flags a new Taiwan export-control risk, with Super Micro the near-term pressure pointThe Apex TimesBusinessNvidia Adds New Variants to Nemotron 3.5 Open AI Model Lineup, While Report Cites Texas Supply Expansion and Customer Debt PressureThe Apex TimesBusinessModerna shares fall after sharp rally as investors reassess valuationThe Apex TimesBusinessMeta launches Muse Spark Open for developers, pairing an open model with its proprietary Muse Wonder systemThe Apex TimesBusinessTesla shares take flight in market chat as iPhone Duo pre-orders sell out and bond yields pause their climbThe Apex TimesBusinessCoreWeave shares fall again as Nvidia’s Jensen Huang’s optimism fails to steady investor sentimentThe Apex TimesBusinessLeftovers: Ghirardelli and PepsiCo lean into TikTok-style flavor and convenience playsThe Apex TimesBusinessModerna shares surge, but some investors are pressing pauseThe Apex TimesBusinessUnitedHealth frames its next growth path around the care it delivers as it lifts 2026 outlookThe Apex Times
Back to front
Eli Lilly trims Germany factory plan as it shifts more spending to the U.S.
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 7, 12:36 AM EDT

Eli Lilly trims Germany factory plan as it shifts more spending to the U.S.

The company will cut in half a planned 2.3 billion euro investment in Germany, while keeping the Alzey project alive at a smaller scale and continuing a major U.S. manufacturing push.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly said it will cut in half a planned 2.3 billion euro investment in Germany, with Chief Executive Dave Ricks telling Handelsblatt that the company is responding to proposed health-care cost rules in the country. Reuters reported that Lilly still sees Europe as a possible manufacturing base, but that the U.S. now makes more sense for the money it is pulling back. Reuters report

The investment was aimed at a high-tech plant in Alzey, in Rhineland-Palatinate, intended to make injectable medicines and pen systems. Reuters said Lilly has already spent more than 1 billion euros on the site, and the project is still scheduled to begin operating in 2027, though at reduced capacity and with roughly half the 1,000 jobs originally planned. Lilly Deutschland announcement

Lilly’s own 2023 announcement described the Alzey project as a 2.3 billion euro commitment, with up to 1,000 workers and construction starting in 2024. The company said then that the plant would expand its global network for injectable drugs and help meet demand for diabetes and obesity treatments. Lilly Deutschland announcement

The German pullback comes as Lilly keeps adding manufacturing capacity in the United States. In May, the company said it would invest another $4.5 billion across two Indiana sites, pushing its total capital commitments in the state since 2020 above $21 billion. Indiana investment release

That U.S. buildout reflects the scale of demand around Lilly’s obesity and diabetes portfolio, led by Mounjaro and Zepbound. In the Indiana release, Lilly said the extra spending is tied to its evolving pipeline and anticipated demand for its medicines, including future production of oral obesity drug Foundayo and the experimental medicine retatrutide. Indiana investment release

Lilly has not disclosed a new final dollar figure for the Germany project in a company announcement, nor has it filed a separate statement outlining the revised site plan. Reuters said the money could instead go to Pennsylvania or to a new U.S. location, but that destination has not been finalized publicly. Reuters report

Why It Matters

  • The move shows how pricing and reimbursement policy can shape where drugmakers build factories.
  • It suggests Lilly is prioritizing U.S. manufacturing even while Europe remains an option.
  • A smaller German buildout could mean fewer jobs and less local economic spillover.
  • The decision does not announcement a wider retreat from capital spending, but it does show Lilly is being selective about where that money goes.

Sources

Key Facts

  • Eli Lilly will halve a previously planned 2.3 billion euro investment in Germany.
  • The project centers on a manufacturing site in Alzey, Rhineland-Palatinate.
  • Reuters said Lilly has already invested more than 1 billion euros at the site.
  • The Alzey plant is still expected to open in 2027, but at reduced capacity.
  • Lilly’s original Germany plan called for up to 1,000 jobs.
  • Lilly recently announced an additional $4.5 billion investment in Indiana manufacturing.

Healthcare Related

Oct 16, 11:14 AM EDT
The Apex Times

Moderna shares surge, but some investors are pressing pause

Moderna (MRNA) stock has jumped sharply in recent months, reaching a one-year high close on Oct. 15, 2026. Still, a new market commentary argues that the rally may not answer all of the questions investors typically weigh before chasing momentum.

Moderna shares surge, but some investors are pressing pause
The Apex Times
Eli Lilly trims Germany factory plan as it shifts more spending to the U.S. | The Apex Times